Healthcare and Biotech Sector Traders!

Discover our trading method for Huge Profit: 810% for 2009, 220% so far for 2010.

The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. It includes: company name, ticker, decision date, and description.

more information Online and Interactive FDA Calendar Events

FDA Calendar is updated Daily and include the following events:

510k
PDUFA
NDA
FDA Panel
Clinical Results
Conference

We enhance the company’s image in the capital market through our quality IR services and business consulting for public companies. To enhance your image and visibility we also develop attractive and professional website for public trading companies.

more informationWe Offer Investors Relation Services

The Clever Bull Investors Relation Services:

Increase company’s shareholder base
Increase your market capitalization
Develop a new and professional website
Provide consulting service
Enhance company’s image and visibility
Capture opportunity to financing

We have been investing in healthcare stocks for 20 years, our method is now revealed in this invaluable eBook and tells the reader how to invest in the healthcare biotechnology sector, one of the fast-growing sectors of the US economy.

more informationThe Clever Bull Method for your Portfolio

How to Invest in Biotech stocks for huge profits! Follow our eBook method:

The Basics of Investing
An Introduction to Biotechnology
Risk Management on Biotech
Understanding the FDA process
How to Value Biotech Stocks
A Unique and Powerful Method

What We Do

Journalism: we are sometimes deeply involved in biotech companies, we then write articles to unveiled the potential of one company.

Trading: our Traders are specialist in biotech field and swing trading...

Development: we develop online financial tools and websites.

Latest News & Articles

24 August, 2010
Alexza on the way to agitate the market
Alexza's lead candidate, AZ-004 is actually under FDA review with an action date schedule for October 11th 2010.We believe that their Staccato platform has the right combination of key attributes for the treatment of acute agitation that makes the product a $500M Market opportunity.